Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to investigate urinary nerve growth factor (NGF) as a biomarker of treatment efficacy and recurrence in overactive bladder (OAB) patients. Methods: We enrolled 189 OAB subjects who visited our outpatient clinic from February 2010 to February 2015. All subjects with OAB received antimuscarinic treatment. A 3-day voiding diary and questionnaire were collected from each patient. Urinary levels of NGF were evaluated at baseline, the beginning of antimuscarinic treatment, and the end of antimuscarinic treatment. Urinary NGF was normalized to urine creatinine (Cr). Between-group comparisons of baseline characteristics were made using the Mann-Whitney U-test. Multivariate logistic regression analyses were used to predict responses to anticholinergic treatment and recurrence. The Wilcoxon signed-rank test with the Bonferroni correction was used for intragroup comparisons. A receiver operating characteristic curve was used to analyze the utility of this biomarker. Results: Urinary levels of NGF/Cr tended to decrease in patients who responded to treatment (n=62), but this was not significant (P=0.260). Urinary NGF levels were higher at baseline in patients who did not experience recurrence than in those who did (P=0.047). In those who did not experience recurrence (n=29), urinary NGF/Cr decreased at the end of treatment compared to baseline, and this reduction was maintained at 12 weeks after the end of treatment (P<0.05). Conclusions: Urinary NGF is a potential biomarker for predicting the outcome of antimuscarinic treatment in OAB patients. This may provide useful information when deciding to stop antimuscarinic treatment in responders.
Abstract
Purpose: The aim of this study was to investigate urinary nerve growth factor (NGF) as a biomarker of treatment efficacy and recurrence in overactive bladder (OAB) patients. Methods: We enrolled 189 OAB subjects who visited our outpatient clinic from February 2010 to February 2015. All subjects with OAB received antimuscarinic treatment. A 3-day voiding diary and questionnaire were collected from each patient. Urinary levels of NGF were evaluated at baseline, the beginning of antimuscarinic treatment, and the end of antimuscarinic treatment. Urinary NGF was normalized to urine creatinine (Cr). Between-group comparisons of baseline characteristics were made using the Mann-Whitney U-test. Multivariate logistic regression analyses were used to predict responses to anticholinergic treatment and recurrence. The Wilcoxon signed-rank test with the Bonferroni correction was used for intragroup comparisons. A receiver operating characteristic curve was used to analyze the utility of this biomarker. Results: Urinary levels of NGF/Cr tended to decrease in patients who responded to treatment (n=62), but this was not significant (P=0.260). Urinary NGF levels were higher at baseline in patients who did not experience recurrence than in those who did (P=0.047). In those who did not experience recurrence (n=29), urinary NGF/Cr decreased at the end of treatment compared to baseline, and this reduction was maintained at 12 weeks after the end of treatment (P<0.05). Conclusions: Urinary NGF is a potential biomarker for predicting the outcome of antimuscarinic treatment in OAB patients. This may provide useful information when deciding to stop antimuscarinic treatment in responders.
참고문헌 (27)
- Haylen BT, "An International Urogynecological Association(IUGA)", International Continence Society(ICS)joint report on the terminology for female pelvic floor dysfunction, 2010, pp.21, 5~26
- Stewart WF, "Prevalence and burden of overactive bladder in the United States", World J Urol, 20, pp.327~336 (2003)
- Lee YS, "Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study", World J Urol, 29, pp.185~190 (2011)
- Sever N, "An investigation of lower urinary tract symptoms in women aged 40 and over", Low Urin Tract Symptoms, 9, pp.21~26 (2017)
- Silva-Ramos M, "Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome", PLoS One, 8, pp.e64696~ (2013)
- Choo MS, "Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent : a prospective trial", J Urol, 174, pp.201~204 (2005)
- Hashim H, "Is the bladder a reliable witness for predicting detrusor overactivity?", J Urol, 175, pp.191~194 (2006)
- Digesu GA, "Should we explain lower urinary tract symptoms to patients?", Neurourol Urodyn, 27, pp.368~371 (2008)
- Fry CH, "What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013", Neurourol Urodyn, 33, pp.602~605 (2014)
- Steers WD, "Mechanisms of Disease : the role of nerve growth factor in the pathophysiology of bladder disorders", Nat Clin Pract Urol, 3, pp.101~110 (2006)
- Chuang YC, "The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor", J Urol, 165, pp.975~979 (2001)
- Antunes-Lopes T, "Urinary neurotrophic factors in healthy individuals and patients with overactive bladder", J Urol, 189, pp.359~365 (2013)
- Kuo HC, "Can urinary nerve growth factor be a biomarker for overactive bladder?", Rev Urol, 12, pp.e69~e77 (2010)
- Liu HT, "Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection", Eur Urol, 56, pp.700~706 (2009)
- 김수림, "NGF and HB-EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome", Yonsei Medical Journal, 56(1), pp.204~211 (2015), 연세대학교의과대학[DOI]
- Vijaya G, "Reliability and validity of urinary nerve growth factor measurement in women with lower urinary tract symptoms", Neurourol Urodyn, 35, pp.944~948 (2016)
- Persson K, "Protein kinase C in cyclic stretch-induced nerve growth factor production by urinary tract smooth muscle cells", Am J Physiol, 269(4 Pt 1), pp.C1018~C1024 (1995)
- Liu HT, "Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis", bladder pain syndrome and detrusor overactivity, 2010, pp.106, 1681~1685
- Liu HT, "Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women", BJU Int, 102, pp.1440~1444 (2008)
- 고일규, "Swimming: Effects on Stress Urinary Incontinence and the Expression of Nerve Growth Factor in Rats Following Transabdominal Urethrolysis", International Neurourology Journal, 15(2), pp.74~81 (2011), 대한배뇨장애요실금학회
- Steers WD, "Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function", J Clin Invest, 88, pp.1709~1715 (1991)
- Liu HT, "Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders", J Formos Med Assoc, 109, pp.862~878 (2010)
- Bhide AA, "Biomarkers in overactive bladder", Int Urogynecol J, 24, pp.1065~1072 (2013)
- Ochodnický P, "Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target", Neurourol Urodyn, 30, pp.1227~1241 (2011)
- Sariola H, "Novel functions and signalling pathways for GDNF", J Cell Sci, 116(Pt 19), pp.3855~3862 (2003)
- Antunes-Lopes T, "Biomarkers in overactive bladder: a new objective and noninvasive tool?", Adv Urol, 2011, pp.382431~ (2011)
- Gamper M, "Have we been led astray by the NGF biomarker data?", Neurourol Urodyn, 36, pp.203~204 (2017)